Who Buys Atorvastatin from India — 1291 Importers Behind a $1.1B Market
India's atorvastatin import market is served by 1291 active buyers who collectively imported $1.1B across 15,000 shipments. APOTEX CORP (UNITED STATES) leads with a 22.4% market share, followed by BIOMEDPHARMA and MYLAN PHARMACEUTICALS INC,. The top 5 buyers together control 61.6% of total import value, reflecting a concentrated buyer landscape.
Top Atorvastatin Importers — Ranked by Import Value
APOTEX CORP (UNITED STATES) is the leading atorvastatin importer from India, holding a 22.4% share of the $1.1B market across 15,000 shipments from 1291 buyers. The top 5 buyers — APOTEX CORP (UNITED STATES), BIOMEDPHARMA (CANADA), MYLAN PHARMACEUTICALS INC, (UNITED STATES), ACCORD HEALTHCARE INC., (CANADA), LIFESCIENCE LOGISTICS (UNITED STATES) — collectively control 61.6% of total import value.
Top Atorvastatin Buyers & Importers
Ranked by import value · 1291 active buyers · Indian Customs (DGFT) data
| # | Buyer & Formulations | Value | Suppliers | Share |
|---|---|---|---|---|
| 1 | APOTEX CORPUNITED STATES ATORVASTATIN CALCIUM TABLETS USP 40 MG 500BT 13536 PACKSPH.DRU.& MED.: ACH-ATORVASTATIN 20MG TABLETS [8315X1X500T]PH.DRU.& MED.: ACH-ATORVASTATIN 40MG TABLETS [2122X1X500T] | $241.6M | 5 | 22.4% |
| 2 | BIOMEDPHARMACANADA PH.DRU.& MED.: ACH-ATORVASTATIN 20MG TABLETS [8315X1X500T]PH.DRU.& MED.: ACH-ATORVASTATIN 40MG TABLETS [2122X1X500T] | $194.2M | 5 | 18.0% |
| 3 | MYLAN PHARMACEUTICALS INC,UNITED STATES ATORVASTATIN CALCIUM TABLETS USP 40 MG 500BT 13536 PACKSPH.DRU.& MED.: ACH-ATORVASTATIN 20MG TABLETS [8315X1X500T]PH.DRU.& MED.: ACH-ATORVASTATIN 40MG TABLETS [2122X1X500T] | $136.0M | 5 | 12.6% |
| 4 | ACCORD HEALTHCARE INC.,CANADA PH.DRU.& MED.: ACH-ATORVASTATIN 20MG TABLETS [8315X1X500T]PH.DRU.& MED.: ACH-ATORVASTATIN 40MG TABLETS [2122X1X500T] | $57.6M | 5 | 5.3% |
| 5 | LIFESCIENCE LOGISTICSUNITED STATES ATORVASTATIN CALCIUM TABLETS USP 40 MG 500BT 13536 PACKSATORVASTATIN 20 MG TABS( BRELVASTIN 20 MOP ATOR - 20MG FILM-COATED TAB) | $36.4M | 5 | 3.4% |
| 6 | ASCEND LABOATORIES,LLC C/O UPSUNITED STATES ATORVASTATIN CALCIUM TABLETS USP 40 MG 500BT 13536 PACKSATORVASTATINA 20 (ATORVASTATINA 20 | $28.0M | 5 | 2.6% |
| 7 | APL SWIFT SERVICES (MALTA) LTD.,MALTA ATORVASTATIN 80 MG TABLETS(ATORVASTATINAATORVASTATIN 20 MG TABLETS(APO-ATORVA,20ATORVASTATIN 40 MG TABLETS(APO-ATORVA,40 | $27.6M | 5 | 2.6% |
| 8 | NOVADOZ PHARMACEUTICALS LLCUNITED STATES ATORVASTATIN CALCIUM TABLETS USP 40 MG 500BT 13536 PACKS | $17.3M | 5 | 1.6% |
| 9 | BIOCON PHARMA INCUNITED STATES ATORVASTATIN CALCIUM TABLETS USP 40 MG 500BT 13536 PACKS | $16.0M | 5 | 1.5% |
| 10 | YUSEN LOGISTICS BENELUX BELGIUMBELGIUM ATORVASTATIN CALCIUM TABLETS 80MG ( ATORATORVASTATIN CALCIUM TABLETS 20MG ( ATORATORVASTATIN CALCIUM TABLETS 40MG ( ATOR | $14.7M | 5 | 1.4% |
| 11 | ICS (BIOCON PHARMA INC)UNITED STATES ATORVASTATIN CALCIUM TABLETS USP 40 MG 500BT 13536 PACKSATORVASTATIN CALCIUM TABLETS 80MG ( ATORATORVASTATIN SZ 40MG EACH FILM COATED TA | $13.4M | 5 | 1.2% |
| 12 | MYLAN PHARMACEUTICALS INCUNITED STATES ATORVASTATIN CALCIUM TABLETS USP 40 MG 500BT 13536 PACKSPH.DRU.& MED.: ACH-ATORVASTATIN 20MG TABLETS [8315X1X500T]PH.DRU.& MED.: ACH-ATORVASTATIN 40MG TABLETS [2122X1X500T] | $11.5M | 5 | 1.1% |
| 13 | ACCORD HEALTHCARE INC.CANADA PH.DRU.& MED.: ACH-ATORVASTATIN 20MG TABLETS [8315X1X500T]PH.DRU.& MED.: ACH-ATORVASTATIN 40MG TABLETS [2122X1X500T] | $9.9M | 5 | 0.9% |
| 14 | MSN LABORATORIES EUROPE LIMITEDUNITED KINGDOM ATORVASTATIN TAB 40 MG X 28'S MSN UKATORVASTATIN TAB 20 MG X 28'S MSN UKATORVASTATIN TAB 20 MG X 28'S MSN UKNOS | $9.5M | 5 | 0.9% |
| 15 | SAWAI PHARMACEUTICAL CO.LTD.JAPAN ATORVASTATIN TABLETS 10MG (ATORVASTATINATORVASTATIN TABLETS 10MG ATORVASTATINATORVASTATIN TABLETS 10 MG, | $6.5M | 5 | 0.6% |
Related Analysis
Market Analysis: Top Importing Countries & Importers
Comprehensive geographic market intelligence dashboard
Which companies are buying Atorvastatin — and from which countries?
Flow of Atorvastatin exports from India: each country's share and the named importers behind the numbers
Atorvastatin — Buyer Countries to Key Importers
Trade flow: top importing countries → named buyer companies
Market Analysis: Top Importing Countries & Their Importers
1United States
United States emerges as the first largest importing country, achieving a total trade value of $567.7M through 1,877 shipments. This represents a market share of 52.5% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: United States has a diverse importer base, with their top importers including:
• APOTEX CORP - $241.6M (42.6% of country's total business)
• MYLAN PHARMACEUTICALS INC, - $136.0M (24.0% of country's total business)
• LIFESCIENCE LOGISTICS - $36.4M (6.4% of country's total business)
• ASCEND LABOATORIES,LLC C/O UPS - $28.0M (4.9% of country's total business)
• NOVADOZ PHARMACEUTICALS LLC - $17.3M (3.0% of country's total business)
• Rest of United States's importers - $108.4M (19.1% of country's total business)
Key Insight: United States demonstrates strong market positioning with an average shipment value of $302.4K, indicating premium pricing strategy compared to the market average of $72.0K.
United States is a key market for Atorvastatin imports, representing 52.5% of total trade value.
2Canada
Canada emerges as the second largest importing country, achieving a total trade value of $279.4M through 141 shipments. This represents a market share of 25.9% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Canada has a diverse importer base, with their top importers including:
• BIOMEDPHARMA - $194.2M (69.5% of country's total business)
• ACCORD HEALTHCARE INC., - $57.6M (20.6% of country's total business)
• ACCORD HEALTHCARE INC. - $9.9M (3.6% of country's total business)
• APOTEX INC, - $5.6M (2.0% of country's total business)
Key Insight: Canada demonstrates strong market positioning with an average shipment value of $2.0M, indicating premium pricing strategy compared to the market average of $72.0K.
Canada is a key market for Atorvastatin imports, representing 25.9% of total trade value.
3Malta
Malta emerges as the third largest importing country, achieving a total trade value of $32.5M through 517 shipments. This represents a market share of 3.0% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Malta has a diverse importer base, with their top importers including:
• APL SWIFT SERVICES (MALTA) LTD., - $27.6M (84.9% of country's total business)
Key Insight: Malta demonstrates strong market positioning with an average shipment value of $62.8K, indicating competitive pricing strategy compared to the market average of $72.0K.
Malta is a key market for Atorvastatin imports, representing 3.0% of total trade value.
4United Kingdom
United Kingdom emerges as the fourth largest importing country, achieving a total trade value of $30.2M through 446 shipments. This represents a market share of 2.8% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: United Kingdom has a diverse importer base, with their top importers including:
• MSN LABORATORIES EUROPE LIMITED - $9.5M (31.3% of country's total business)
• MSN LABORATORIES EUROPE LIMITED., - $5.3M (17.6% of country's total business)
Key Insight: United Kingdom demonstrates strong market positioning with an average shipment value of $67.7K, indicating competitive pricing strategy compared to the market average of $72.0K.
United Kingdom is a key market for Atorvastatin imports, representing 2.8% of total trade value.
5Japan
Japan emerges as the fifth largest importing country, achieving a total trade value of $26.8M through 48 shipments. This represents a market share of 2.5% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Japan has a diverse importer base, with their top importers including:
• SAWAI PHARMACEUTICAL CO.LTD. - $6.5M (24.4% of country's total business)
Key Insight: Japan demonstrates strong market positioning with an average shipment value of $557.6K, indicating premium pricing strategy compared to the market average of $72.0K.
Japan is a key market for Atorvastatin imports, representing 2.5% of total trade value.
Buyer Segment Analysis
TransData Nexus Atorvastatin buyer market intelligence
1Buyer Segment Analysis
The 1,291 buyers of Atorvastatin imported from India can be categorized into several segments:
1. Distributors: Entities like APOTEX CORP (United States, $241.63M) and BIOMEDPHARMA (Canada, $194.21M) function as intermediaries, purchasing large quantities to supply to various healthcare providers. Their buying behavior is characterized by bulk orders and a high repeat purchase rate, ensuring a steady supply chain.
2. Contract Manufacturers: Companies such as MYLAN PHARMACEUTICALS INC. (United States, $136.03M) and ACCORD HEALTHCARE INC. (Canada, $57.64M) procure Atorvastatin for formulation and packaging under their brand names. They typically engage in consistent, large-scale purchases aligned with their production schedules.
3. Re-exporters: Entities like APL SWIFT SERVICES (Malta) LTD. (Malta, $27.55M) and YUSEN LOGISTICS BENELUX BELGIUM (Belgium, $14.69M) import Atorvastatin for redistribution to other markets. Their purchasing patterns are influenced by global demand fluctuations and trade agreements.
4. Retail Chains and Hospital Groups: While not explicitly listed among the top buyers, these segments procure Atorvastatin through distributors or directly for patient care. Their orders are typically smaller and more frequent, based on patient demand and prescription trends.
5. Government Procurement: Organizations like UNICEF and national health departments may engage in tender-based purchasing for public health programs. Their procurement is often large-scale but less frequent, aligned with budget cycles and public health initiatives.
Country-Specific Import Regulations
TransData Nexus Atorvastatin buyer market intelligence
1Country-Specific Import Regulations
United States
1. Drug Regulatory Authority: U.S. Food and Drug Administration (FDA).
2. Import Registration Process: Importers must ensure that Atorvastatin is FDA-approved and manufactured in FDA-inspected facilities. The FDA regulates all human and animal drugs in the United States.
3. Estimated Timeline for Registration: The FDA's drug approval process can take several months to years, depending on the complexity of the application and the need for inspections.
4. Import Tariff/Duty for HS 30049099: Pharmaceutical products under HS code 30049099 are generally duty-free in the United States.
Canada
1. Drug Regulatory Authority: Health Canada.
2. Import Registration Process: Importers must obtain a Drug Establishment License (DEL) and ensure that Atorvastatin complies with the Food and Drugs Act and Regulations. Health Canada maintains a list of drugs for exceptional importation and sale, which is updated as required. (canada.ca)
3. Estimated Timeline for Registration: The registration process can take several months, depending on the completeness of the application and any required inspections.
4. Import Tariff/Duty for HS 30049099: Pharmaceutical products under HS code 30049099 are typically duty-free in Canada.
Malta
1. Drug Regulatory Authority: Malta Medicines Authority.
2. Import Registration Process: Importers must ensure that Atorvastatin is authorized for sale in Malta, complying with the Medicines Act and subsidiary legislation.
3. Estimated Timeline for Registration: The registration process can take several months, subject to the evaluation of the application and any necessary inspections.
4. Import Tariff/Duty for HS 30049099: As a member of the European Union, Malta applies the EU's Common External Tariff, which generally imposes no duties on pharmaceutical products under HS code 30049099.
United Kingdom
1. Drug Regulatory Authority: Medicines and Healthcare products Regulatory Agency (MHRA).
2. Import Registration Process: Importers must hold a Wholesale Dealer's License and ensure that Atorvastatin is authorized for sale in the UK, complying with the Human Medicines Regulations.
3. Estimated Timeline for Registration: The registration process can take several months, depending on the complexity of the application and any required inspections.
4. Import Tariff/Duty for HS 30049099: Pharmaceutical products under HS code 30049099 are generally duty-free in the UK.
Japan
1. Drug Regulatory Authority: Pharmaceuticals and Medical Devices Agency (PMDA).
2. Import Registration Process: Importers must obtain a Foreign Manufacturer Accreditation and ensure that Atorvastatin complies with the Pharmaceutical and Medical Device Act.
3. Estimated Timeline for Registration: The registration process can take 12 to 18 months, including the time required for document review and facility inspections.
4. Import Tariff/Duty for HS 30049099: Pharmaceutical products under HS code 30049099 are generally duty-free in Japan.
Demand Drivers & Market Opportunity
TransData Nexus Atorvastatin buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Atorvastatin in importing countries is driven by several factors:
1. Disease Prevalence: Cardiovascular diseases (CVDs) are the leading cause of death globally, accounting for approximately 17.9 million deaths annually. Atorvastatin is widely prescribed to manage cholesterol levels and reduce the risk of CVDs.
2. Government Healthcare Programs: Many countries have national health programs that subsidize or provide free access to essential medicines, including Atorvastatin, to manage public health concerns related to heart disease.
3. Universal Health Coverage Expansion: The global push towards Universal Health Coverage (UHC) has led to increased access to essential medicines. The WHO emphasizes the importance of essential medicines in achieving UHC, noting that over 150 countries have adopted national lists based on the WHO Model List. (who.int)
4. WHO Essential Medicines List Procurement: Atorvastatin is included in the WHO Model List of Essential Medicines, guiding countries in their procurement strategies to ensure the availability of critical medications. (iris.who.int)
5. Tender-Based Purchasing: Government and international organizations often procure medicines through tenders to ensure cost-effectiveness and supply chain stability. The presence of 1,291 buyers across 145 countries indicates a robust and diverse market for Atorvastatin, reflecting its global importance in managing cardiovascular health.
In summary, the buyer landscape for Atorvastatin imported from India is diverse, encompassing distributors, contract manufacturers, re-exporters, and healthcare providers. Understanding the import regulations of key markets and the factors driving demand is crucial for stakeholders aiming to navigate and succeed in the global pharmaceutical market.
Common Questions — Atorvastatin Buyers & Importers
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
QWho is the largest atorvastatin buyer importing from India?
Based on import volume and value, APOTEX CORP (UNITED STATES) leads with $241.6M in imports and a 22.4% market share — the highest of any single atorvastatin importer. BIOMEDPHARMA (CANADA) and MYLAN PHARMACEUTICALS INC, (UNITED STATES) are the next largest buyers.
QHow many companies buy atorvastatin from India?
There are 1291 active atorvastatin buyers importing from India, with a combined market of $1.1B across 15,000 shipments to 145 countries. The top 5 buyers hold 61.6% of total import value, while the remaining 1286 buyers handle the other 38.4%.
QWhich countries import the most atorvastatin from India?
The top importing countries for atorvastatin from India are United States (52.5%), Canada (25.9%), Malta (3.0%), United Kingdom (2.8%), Japan (2.5%). These markets represent the largest demand centres for Indian pharmaceutical exports of atorvastatin, with buyers ranging from government procurement agencies to private pharmaceutical distributors.
QWhat is the average import order value for atorvastatin from India?
The average import transaction value for atorvastatin from India is $72.0K, with an average unit price of $6.13 per unit. Order sizes vary significantly based on buyer type — government tenders tend to be larger while private distributors place more frequent smaller orders.
Buyer Segment Analysis
TransData Nexus Atorvastatin buyer market intelligence
1Buyer Segment Analysis
The 1,291 buyers of Atorvastatin imported from India can be categorized into several segments:
1. Distributors: Entities like APOTEX CORP (United States, $241.63M) and BIOMEDPHARMA (Canada, $194.21M) function as intermediaries, purchasing large quantities to supply to various healthcare providers. Their buying behavior is characterized by bulk orders and a high repeat purchase rate, ensuring a steady supply chain.
2. Contract Manufacturers: Companies such as MYLAN PHARMACEUTICALS INC. (United States, $136.03M) and ACCORD HEALTHCARE INC. (Canada, $57.64M) procure Atorvastatin for formulation and packaging under their brand names. They typically engage in consistent, large-scale purchases aligned with their production schedules.
3. Re-exporters: Entities like APL SWIFT SERVICES (Malta) LTD. (Malta, $27.55M) and YUSEN LOGISTICS BENELUX BELGIUM (Belgium, $14.69M) import Atorvastatin for redistribution to other markets. Their purchasing patterns are influenced by global demand fluctuations and trade agreements.
4. Retail Chains and Hospital Groups: While not explicitly listed among the top buyers, these segments procure Atorvastatin through distributors or directly for patient care. Their orders are typically smaller and more frequent, based on patient demand and prescription trends.
5. Government Procurement: Organizations like UNICEF and national health departments may engage in tender-based purchasing for public health programs. Their procurement is often large-scale but less frequent, aligned with budget cycles and public health initiatives.
Country-Specific Import Regulations
TransData Nexus Atorvastatin buyer market intelligence
1Country-Specific Import Regulations
United States
1. Drug Regulatory Authority: U.S. Food and Drug Administration (FDA).
2. Import Registration Process: Importers must ensure that Atorvastatin is FDA-approved and manufactured in FDA-inspected facilities. The FDA regulates all human and animal drugs in the United States.
3. Estimated Timeline for Registration: The FDA's drug approval process can take several months to years, depending on the complexity of the application and the need for inspections.
4. Import Tariff/Duty for HS 30049099: Pharmaceutical products under HS code 30049099 are generally duty-free in the United States.
Canada
1. Drug Regulatory Authority: Health Canada.
2. Import Registration Process: Importers must obtain a Drug Establishment License (DEL) and ensure that Atorvastatin complies with the Food and Drugs Act and Regulations. Health Canada maintains a list of drugs for exceptional importation and sale, which is updated as required. (canada.ca)
3. Estimated Timeline for Registration: The registration process can take several months, depending on the completeness of the application and any required inspections.
4. Import Tariff/Duty for HS 30049099: Pharmaceutical products under HS code 30049099 are typically duty-free in Canada.
Malta
1. Drug Regulatory Authority: Malta Medicines Authority.
2. Import Registration Process: Importers must ensure that Atorvastatin is authorized for sale in Malta, complying with the Medicines Act and subsidiary legislation.
3. Estimated Timeline for Registration: The registration process can take several months, subject to the evaluation of the application and any necessary inspections.
4. Import Tariff/Duty for HS 30049099: As a member of the European Union, Malta applies the EU's Common External Tariff, which generally imposes no duties on pharmaceutical products under HS code 30049099.
United Kingdom
1. Drug Regulatory Authority: Medicines and Healthcare products Regulatory Agency (MHRA).
2. Import Registration Process: Importers must hold a Wholesale Dealer's License and ensure that Atorvastatin is authorized for sale in the UK, complying with the Human Medicines Regulations.
3. Estimated Timeline for Registration: The registration process can take several months, depending on the complexity of the application and any required inspections.
4. Import Tariff/Duty for HS 30049099: Pharmaceutical products under HS code 30049099 are generally duty-free in the UK.
Japan
1. Drug Regulatory Authority: Pharmaceuticals and Medical Devices Agency (PMDA).
2. Import Registration Process: Importers must obtain a Foreign Manufacturer Accreditation and ensure that Atorvastatin complies with the Pharmaceutical and Medical Device Act.
3. Estimated Timeline for Registration: The registration process can take 12 to 18 months, including the time required for document review and facility inspections.
4. Import Tariff/Duty for HS 30049099: Pharmaceutical products under HS code 30049099 are generally duty-free in Japan.
Demand Drivers & Market Opportunity
TransData Nexus Atorvastatin buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Atorvastatin in importing countries is driven by several factors:
1. Disease Prevalence: Cardiovascular diseases (CVDs) are the leading cause of death globally, accounting for approximately 17.9 million deaths annually. Atorvastatin is widely prescribed to manage cholesterol levels and reduce the risk of CVDs.
2. Government Healthcare Programs: Many countries have national health programs that subsidize or provide free access to essential medicines, including Atorvastatin, to manage public health concerns related to heart disease.
3. Universal Health Coverage Expansion: The global push towards Universal Health Coverage (UHC) has led to increased access to essential medicines. The WHO emphasizes the importance of essential medicines in achieving UHC, noting that over 150 countries have adopted national lists based on the WHO Model List. (who.int)
4. WHO Essential Medicines List Procurement: Atorvastatin is included in the WHO Model List of Essential Medicines, guiding countries in their procurement strategies to ensure the availability of critical medications. (iris.who.int)
5. Tender-Based Purchasing: Government and international organizations often procure medicines through tenders to ensure cost-effectiveness and supply chain stability. The presence of 1,291 buyers across 145 countries indicates a robust and diverse market for Atorvastatin, reflecting its global importance in managing cardiovascular health.
In summary, the buyer landscape for Atorvastatin imported from India is diverse, encompassing distributors, contract manufacturers, re-exporters, and healthcare providers. Understanding the import regulations of key markets and the factors driving demand is crucial for stakeholders aiming to navigate and succeed in the global pharmaceutical market.
Official References & Regulatory Resources
- European Medicines Agency
- WHO Essential Medicines
- Invest India — Pharma Sector
- India Trade Statistics (DGFT)
Verify import regulations and drug registration requirements with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Buyer Identification: 1291 global importers of Atorvastatin identified from consignee fields in DGFT shipping bill records.
- 2.Import Value Analysis: Total import value aggregated from 15,000 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Geographic Distribution: Buyer imports distributed across 145 destination countries with market share per buyer calculated from capped values.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
15,000 Verified Shipments
1291 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists